PATENT CLAIM ANALYSIS

Application Number: 16217668
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-08
Patent Classification: ["436", "547000"]

Abstract:
The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.

Claim (Index 6):
The method of  claim 5 , wherein said glutamate receptor antagonist is selected from the group consisting of 1-amino-3,5-dimethyl-adamantane, 1-aminoadamantane, (+)-3-methoxy-17-methyl-(9\u03b1,13\u03b1,14\u03b1)-morphinan, 17-methyl-9a,13a,14a-morphinan-3-ol, 2-(2-chlorophenyl)-2-methylamino-cyclohexan-1-one, 1-(1-phenylcyclohexyl)piperidine, (\u00b1)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride, and 6-(Dimethylamino)-4,4-diphenylheptan-3-one.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 98.0
- Lexical Diversity: 1.38889
- Patent Class: 436.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12573942', '14113061', '14442731', '14539405', '13130196']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6771643196733477
- 35 USC 102 Novelty (BERT): 0.5149326429574487
- Combined Prediction Score: 0.6609411520017577
- Mean Citation Score: 192.914812
- Max Citation Score: 326.98245
- Similarity Product: 209.5037697968602

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test